| Value | ₹1,833 Cr |
|---|
BSE filing, NSE: SPARC. Summary written from the filing by ALFA Finder's alert engine.
Sun Pharma Advanced Research Company Ltd: key numbers
- Share price
- ₹185.37
- Market cap
- ₹6,016 Cr
- Revenue (annual)
- ₹1,879 Cr
- Net profit (annual)
- ₹1,553 Cr
- P/E (TTM)
- 3.7×Sector 41.3×
- Promoter holding
- 65.67%+0.00% QoQ
- FII holding
- 3.74%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Sun Pharma Advanced Research Company Ltd
All →Sun Pharma Advanced Research Company Other Announcement
Sun Pharma Advanced Research filed its monitoring agency report on warrant issue proceeds for the quarter ended September 30, 2026. The agency found no deviation from objects.
Sun Pharma Advanced Research Company Q2 FY27 Results: Net Loss of ₹24.4 Cr, Loss Narrows
Sun Pharma Advanced Research Company Ltd reported revenue from operations of ₹30 Cr (+279.7% YoY) and a net loss of ₹24.4 Cr for Q2 FY27.
- Key figure
- Net loss ₹24.4 Cr
Sun Pharma Advanced Research Company Board Meeting Date
SPARC intimated its Board will meet November 2, 2026 to consider Q1 and H1 FY27 unaudited results. Insider trading window stays closed until 48 hours post-declaration.
Sun Pharma Advanced Research Company Other Announcement
Sun Pharma Advanced Research Company Ltd has filed its quarterly shareholding pattern under Regulation 31(1)(b) for the quarter ended September 30, 2026.
Sun Pharma Advanced Research Company Legal & Regulatory
The company secured a favorable CESTAT order confirming its entitlement to a Rs. 27.51 Crore CENVAT credit refund. This concludes the litigation in the company's favor.
- Value
- ₹27.51 Cr
Sun Pharma Advanced Research Company Other Announcement
Sun Pharma Advanced Research Company Ltd has filed its quarterly shareholding pattern for the period ended June 30, 2026.
Other merger & restructuring announcements
All →Aurobindo Pharma Merger & Restructuring Worth ₹29 Cr
Aurobindo Pharma approved transferring 100% of Auro Pharma LLC, Russia, between wholly owned subsidiaries. Cash consideration is about INR 29 crore, subject to adjustments.
- Value
- ₹29.00 Cr
- Execution
- 60-90 days
Choice International Merger & Restructuring Worth ₹1.27 Cr
Choice International sold a unit or subsidiary to Arrowbridge Trade for Rs.1.275 Crore in cash. The buyer is unrelated and the deal is at arm's length.
- Value
- ₹1.27 Cr
Shringar House of Mangalsutra Merger & Restructuring Worth ₹5 Cr
Shringar House of Mangalsutra will incorporate a wholly owned jewellery subsidiary, subscribing Rs 5 Crore in cash. The subsidiary becomes a related party once formed.
- Value
- ₹5.00 Cr
HEG Advanced Materials Merger & Restructuring Worth ₹10.12 Cr
HEG Advanced Materials closed LNJ Trading FZCO, its Dubai-based wholly owned subsidiary, as part of overseas structure rationalisation. The filing quantifies the effect at AED 4,048,000.
- Value
- ₹10.12 Cr
Saregama India Merger & Restructuring
Saregama India's board approved closing its wholly owned Dubai subsidiary, Saregama FZE, which has no ongoing operations. The closure is not expected to materially affect business operations.
Jindal Poly Films Merger & Restructuring
Jindal Poly Films' step-down subsidiary, JPF API Laminates UK Limited, was dissolved effective November 3, 2026. It has ceased to be a subsidiary of the company.